SCHEMBL22010517

SCHEMBL22010517

COC(O)C1(CS(=O)(=O)N[Si](c2ccccc2)(c2ccccc2)C(C)(C)C)COC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25014712 0.80 GAA (0.32) —
SCHEMBL21962953 0.68 LMNA (0.41) —
SCHEMBL25014616 0.68 KCNN4 (0.37) —
SCHEMBL21962948 0.66 LMNA (0.39) —
SCHEMBL21962888 0.64 GAA (0.38) —
SCHEMBL28613140 0.64 PTGES2 (0.32) —
SCHEMBL22266027 0.64 KEAP1 (0.41) —
SCHEMBL22266023 0.63 ALDH1A1 (0.33) —
SCHEMBL22687481 0.62 SMYD2 (0.38) —
SCHEMBL28628662 0.62 RAB9A (0.34) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020102100-A9 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY NOVARTIS AG (CH) 2022-01-06 — — WO disclosed
WO-2020102100-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY NOVARTIS INFLAMMASOME RESEARCH, INC. (US) 2020-05-22 — — WO disclosed
Send feedback